Browsing by Author "Brinkmann, Annika"

Now showing 1 - 2 of 2

Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study
(MDPI, 2019-01-01) Bellikci-Koyu, Ezgi; Sarer-Yurekli, Banu Pinar; Akyon, Yakut; Aydin-Kose, Fadime; Karagozlu, Cem; Ozgen, Ahmet Gokhan; Brinkmann, Annika; Nitsche, Andreas; Ergunay, Koray; Yilmaz, Engin; Buyuktuncer, Zehra
Several health-promoting effects of kefir have been suggested, however, there is limited evidence for its potential effect on gut microbiota in metabolic syndrome This study aimed to investigate the effects of regular kefir consumption on gut microbiota composition, and their relation with the components of metabolic syndrome. In a parallel-group, randomized, controlled clinical trial setting, patients with metabolic syndrome were randomized to receive 180 mL/day kefir (n = 12) or unfermented milk (n = 10) for 12 weeks. Anthropometrical measurements, blood samples, blood pressure measurements, and fecal samples were taken at the beginning and end of the study. Fasting insulin, HOMA-IR, TNF-alpha, IFN-gamma, and systolic and diastolic blood pressure showed a significant decrease by the intervention of kefir (p <= 0.05, for each). However, no significant difference was obtained between the kefir and unfermented milk groups (p > 0.05 for each). Gut microbiota analysis showed that regular kefir consumption resulted in a significant increase only in the relative abundance of Actinobacteria (p = 0.023). No significant change in the relative abundance of Bacteroidetes, Proteobacteria or Verrucomicrobia by kefir consumption was obtained. Furthermore, the changes in the relative abundance of sub-phylum bacterial populations did not differ significantly between the groups (p > 0.05, for each). Kefir supplementation had favorable effects on some of the metabolic syndrome parameters, however, further investigation is needed to understand its effect on gut microbiota composition.
Probable alterations in fecal bacterial microbiota by somatostatin receptor analogs in acromegaly
(WALTER DE GRUYTER GMBH, 2020-01-01) Sendur, Suleyman Nahit; Ergunay, Koray; Akyon, Yakut; Brinkmann, Annika; Serdar, Muhittin; Dagdelen, Selcuk; Erbas, Tomris; Nitsche, Andreas; Yilmaz, Engin
Objective: Data on bacterial diversity and microbiota alterations in acromegaly are currently lacking. The effects of somatostatin receptor analogs on gut microbiota remain unknown. The objective of this study was to determine microbiota alterations in patients with acromegaly and to assess the effects of somatostatin receptor analogs on gut microbiota. Methods: The study was designed as a cross-sectional case-control research and three cohorts, comprising individuals with acromegaly without medical therapy (n=5), acromegaly receiving octreotide acetate (OCT) (n=8) and healthy controls (n=5), were evaluated. Results: No statistically-supported changes in Bacteroidetes, Firmicutes, Proteobacteria and Actinobacteria abundance were observed. Bacteroidaceae, Odoribacteraceae, Porphyromonadaceae, Prevotellaceae and Alistipes families of Bacteroidetes and Bifidobacterium genus of the Actinobacteria phyla were detected, without overt differences. Variations in Clostridia, Erysipelotrichaceae and Veillonellaceae were not significant, while Lactobacillales were increased in individuals receiving OCT. Moreover, Akkermansia mucinophila was present in patients under OCT treatment. Conclusion: Our preliminary results suggest that the bacterial community profile under OCT treatment may facilitate a colonic microenvironment for improved glucose metabolism. Alterations in the gut microbiota may be a factor affecting diabetes development during somatostatin analog treatment in acromegalic patients.